Nano PharmaSolutions

Nano PharmaSolutions, founded with the mission to enhance drug bioavailability, focuses on improving the solubility of poorly soluble drugs using innovative nanoformulation. Their core technology, a patented phase-transition platform, enhances the solubility of BCS 2 and BCS 4 APIs without relying on excipients like large volumes of volatile solvents. This technology, known as NanoTransformer™, is designed to deposit vaporized API onto the surface of a carrier, providing a reliable solution for drug formulation across all phases—preclinical, clinical, and commercialization.

Notable figures associated with Nano PharmaSolutions include experts in pharmaceutical sciences and technology innovation. The company has attracted attention from key investors in the biotech and pharmaceutical sectors. Among its significant achievements is the successful application of its nanoformulation technology in enhancing the bioavailability of multiple drug candidates, positioning it as a leader in the field. The overall impact of Nano PharmaSolutions is evident in its contribution to making poorly soluble drugs more effective, thereby improving patient outcomes and advancing pharmaceutical development.